MA41459A - Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l - Google Patents

Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l

Info

Publication number
MA41459A
MA41459A MA041459A MA41459A MA41459A MA 41459 A MA41459 A MA 41459A MA 041459 A MA041459 A MA 041459A MA 41459 A MA41459 A MA 41459A MA 41459 A MA41459 A MA 41459A
Authority
MA
Morocco
Prior art keywords
cd40l
illnesses
disorders
methods
treating
Prior art date
Application number
MA041459A
Other languages
English (en)
Inventor
Alan Gill
Cynthia A Gill
Bingbing Jiang
John M Lincecum
Steven N Perrin
Fernando G Vieira
Original Assignee
Als Therapy Development Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst filed Critical Als Therapy Development Inst
Publication of MA41459A publication Critical patent/MA41459A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
MA041459A 2015-02-03 2016-02-01 Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l MA41459A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562111261P 2015-02-03 2015-02-03

Publications (1)

Publication Number Publication Date
MA41459A true MA41459A (fr) 2017-12-12

Family

ID=56564599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041459A MA41459A (fr) 2015-02-03 2016-02-01 Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l

Country Status (15)

Country Link
US (6) US10106618B2 (fr)
EP (2) EP3253412B1 (fr)
JP (4) JP6797810B2 (fr)
KR (2) KR102747565B1 (fr)
CN (2) CN108064168B (fr)
AU (3) AU2016215505B8 (fr)
CA (1) CA2974135A1 (fr)
DK (1) DK3253412T3 (fr)
GB (1) GB2552429A (fr)
IL (3) IL322241A (fr)
MA (1) MA41459A (fr)
MX (2) MX392480B (fr)
RU (1) RU2727646C2 (fr)
SG (2) SG10201912752QA (fr)
WO (1) WO2016126702A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3556774B1 (fr) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anticorps anti-cd40 et leurs utilisations
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
MA50435A (fr) * 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
JP7775080B2 (ja) * 2019-07-01 2025-11-25 トニックス ファーマ リミテッド 抗ｃｄ１５４抗体およびその使用
WO2021006604A1 (fr) * 2019-07-08 2021-01-14 주식회사 프로젠 Nouvelle protéine de fusion et son utilisation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20240059781A1 (en) * 2021-01-06 2024-02-22 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (fr) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation de réponses immunitaires à des vecteurs viraux
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
KR20230108156A (ko) * 2022-01-10 2023-07-18 주식회사 금호에이치티 Cd40l에 특이적으로 결합하는 항체 및 그의 용도
EP4688856A1 (fr) 2023-04-03 2026-02-11 Regeneron Pharmaceuticals, Inc. Méthodes pour améliorer la survie d'une greffe à l'aide d'anticorps à chaîne gamma du récepteur il-2
WO2025117849A1 (fr) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Méthodes et compositions pour la prévention du rejet de greffe
WO2025235670A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Utilisation d'anticorps anti-ligand cd40 pour l'immunosuppression dans une transplantation de cellules d'îlots
WO2025235683A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Procédés et compositions pour la prévention du rejet de greffe

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (fr) 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
WO1995006481A1 (fr) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
NZ337072A (en) 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
WO1998052606A1 (fr) 1997-05-17 1998-11-26 Biogen, Inc. Utilisation d'un interrupteur de fixation cd40:cd154 pour prevenir les reponses immunitaires indesirables, en particulier le rejet de greffe
KR20010072564A (ko) 1998-04-03 2001-07-31 존 에프. 카바나프 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001034194A1 (fr) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Traitement de tumeurs malignes des cellules b a l'aide d'anticorps anti-cd40l associes a des anticorps anti-cd20, et/ou chimiotherapie et radiotherapie
CN100490895C (zh) 2000-02-01 2009-05-27 泛遗传学公司 结合cd40的apc激活分子
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
BR0110779A (pt) * 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002018540A2 (fr) 2000-09-01 2002-03-07 Biogen, Inc. Nouveaux composes interrompant la fixation de cd40 et de cd154 et leur utilisation pour traiter des complications immunologiques
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003284968A1 (en) 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
JP2007527703A (ja) 2003-07-08 2007-10-04 ジェネスト アー／エス 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー
NZ580688A (en) 2003-07-26 2012-03-30 Biogen Idec Inc Method of designing altered antibodies having improved antigen-binding affinity
NZ545776A (en) * 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
EP2399936A3 (fr) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anticorps anti-CD154
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101198347A (zh) * 2005-04-06 2008-06-11 布里斯托尔-迈尔斯斯奎布公司 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法
WO2006138316A2 (fr) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methodes permettant d'administrer des molecules au systeme nerveux central
KR100772247B1 (ko) 2005-11-04 2007-11-01 엘지전자 주식회사 평면 디스플레이 기기 및 평면 디스플레이 기기의 냉각장치
JP5396083B2 (ja) 2005-11-17 2014-01-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血小板凝集アッセイ
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US7647438B1 (en) * 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
EP2125894B1 (fr) * 2007-03-22 2018-12-19 Biogen MA Inc. Protéines de liaison, incluant des anticorps, dérivés d'anticorps et fragments d'anticorps, qui se lient spécifiquement à cd154 et leurs utilisations
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
MX2011000616A (es) 2008-07-17 2011-02-24 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos.
GB0815788D0 (en) 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
ES2650267T3 (es) 2008-12-05 2018-01-17 Als Therapy Development Institute Método para el tratamiento de enfermedades neurodegenerativas
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2010085682A2 (fr) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation
US20120100166A1 (en) * 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
WO2012103218A1 (fr) 2011-01-25 2012-08-02 University Of South Florida Modèle transgénique de la maladie d'alzheimer
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
CA2832281C (fr) 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anticorps anti-cd154 ayant une liaison deterioree au fcr et/ou des proprietes de liaison au complement deterioree et leur utilisation dans des therapies immunologiques
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
AR086360A1 (es) * 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CN103998995B (zh) 2011-12-08 2016-12-28 普雷斯弗雷克斯股份公司 低体积精密波纹管
KR102133060B1 (ko) 2012-05-11 2020-07-10 메디뮨 리미티드 Ｃｔｌａ－４ 변이체
CN105121621B (zh) 2012-10-18 2019-08-02 张永新 用于细胞动静态交替培养的生物反应器系统及其方法
AU2014250434B2 (en) * 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2015035215A1 (fr) * 2013-09-05 2015-03-12 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
EA201691634A1 (ru) * 2014-03-19 2016-11-30 Бристол-Маерс Сквибб Компани Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MA50435A (fr) 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques

Also Published As

Publication number Publication date
CN108064168A (zh) 2018-05-22
AU2024204572A1 (en) 2024-09-19
KR20250007045A (ko) 2025-01-13
MX2022005655A (es) 2022-06-29
US11692040B2 (en) 2023-07-04
CN114195895B (zh) 2024-09-06
GB2552429A (en) 2018-01-24
JP2023036717A (ja) 2023-03-14
AU2016215505B8 (en) 2021-11-11
US12275793B2 (en) 2025-04-15
CN114195895A (zh) 2022-03-18
KR20170108024A (ko) 2017-09-26
NZ733621A (en) 2024-07-05
IL253571A0 (en) 2017-09-28
RU2727646C2 (ru) 2020-07-22
EP4071175A1 (fr) 2022-10-12
GB201713871D0 (en) 2017-10-11
EP3253412A1 (fr) 2017-12-13
MX392480B (es) 2025-03-24
EP3253412A4 (fr) 2018-08-01
AU2022200323A1 (en) 2022-02-17
RU2017126997A3 (fr) 2019-09-19
US20190092868A1 (en) 2019-03-28
RU2017126997A (ru) 2019-03-04
US20210269538A1 (en) 2021-09-02
SG10201912752QA (en) 2020-02-27
IL253571B (en) 2022-04-01
JP2018510132A (ja) 2018-04-12
AU2016215505B2 (en) 2021-10-28
WO2016126702A1 (fr) 2016-08-11
US10106618B2 (en) 2018-10-23
US20200277391A1 (en) 2020-09-03
US20250263493A1 (en) 2025-08-21
US11014990B2 (en) 2021-05-25
IL322241A (en) 2025-09-01
JP2021054826A (ja) 2021-04-08
JP2025081304A (ja) 2025-05-27
IL287823A (en) 2022-01-01
SG11201706258WA (en) 2017-08-30
CA2974135A1 (fr) 2016-08-11
US20240043549A1 (en) 2024-02-08
DK3253412T3 (da) 2022-05-23
AU2016215505A1 (en) 2017-07-27
US10683356B2 (en) 2020-06-16
AU2022200323B2 (en) 2024-07-25
CN108064168B (zh) 2021-10-26
KR102747565B1 (ko) 2024-12-27
AU2016215505A2 (en) 2019-01-24
US20170342158A1 (en) 2017-11-30
JP6797810B2 (ja) 2020-12-09
EP3253412B1 (fr) 2022-03-23
MX2017009694A (es) 2018-03-15

Similar Documents

Publication Publication Date Title
MA41459A (fr) Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3364993A4 (fr) Procédés pour traiter le syndrome d'angelman et des troubles associés
EP3139914C0 (fr) Composés pour traiter des maladies et des troubles ophtalmiques
EP3551052A4 (fr) Procédés et systèmes pour identifier des troubles cérébraux
EP3692075A4 (fr) Thérapies géniques pour troubles lysosomaux
MA51315A (fr) Compositions et méthodes permettant de traiter des troubles du snc
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
MA44886A (fr) Compositions et méthode pour traiter des troubles acide-base
HUE051488T2 (hu) Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
DK3485890T3 (da) Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr
MA46315A (fr) Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
EP2807412A4 (fr) Procédés et systèmes de surveillance nerveuse pour le traitement de troubles pharyngés
HUE049014T2 (hu) Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
EP2903619A4 (fr) Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
MA51075A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
EP3852653C0 (fr) Appareil d'évaluation de dysfonctionnement microvasculaire
EP3474162A4 (fr) Dispositif et procédé réparti de traitement de données en flux continu distribué
EP3703706A4 (fr) Compositions et méthode pour traiter des troubles acide-base
EP3471746A4 (fr) Méthode et composition pour traiter des troubles epileptiques
IL270543A (en) Treatment methods for recurrent glioblastoma (RGBM)
EP3368047A4 (fr) Composition synthétique et procédé de modulation des troubles émotionnels et de l'humeur
EP3454885A4 (fr) Peptides et méthodes permettant de traiter des troubles neurodégénératifs
EP3411031A4 (fr) Compositions de dompéridone deutérée et méthodes pour la thérapie de troubles